GlassScriptPhysician profile
Richard Michael Harris
NPI 1104904051
$2,185.37
in general payments reported to CMS, 2019-2025
20 companies · $580 in 2025
The $580 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $221 · 2022: $175 · 2023: $417 · 2024: $302 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260 · Consulting Fee: $39.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.13 |
| Consulting Fee | $39.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $323.52 | 2019-2025 | |
| Pharming Healthcare, INC. | $307.76 | 2020-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $180.82 | 2020-2025 | Takhzyro, Cuvitru |
| Shire North American Group INC | $135.94 | 2019 | |
| Csl Behring | $135.88 | 2023-2025 | Haegarda, Hizentra, Andembry |
| Regeneron Healthcare Solutions, INC. | $135.01 | 2019-2023 | Dupixent |
| Amgen INC. | $129.04 | 2022-2024 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $118.53 | 2019-2023 | Airsupra |
| Novartis Pharmaceuticals Corporation | $108.69 | 2019-2025 | |
| Octapharma USA, INC. | $88.82 | 2019-2023 | Panzyga, Cutaquig |
| Biocryst US Sales Co., LLC | $88.31 | 2023-2025 | Orladeyo |
| Grifols USA, LLC | $86.30 | 2024-2025 | Xembify |
| Cycle Pharmaceuticals INC | $65.87 | 2025 | Sajazir |
| Bio Products Laboratory USA, INC. | $64.74 | 2019-2023 | Coagadex, Gammaplex |
| Genentech USA, INC. | $58.09 | 2019-2024 | Xolair |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $54.23 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $39.48 | 2025 | |
| Ionis Pharmaceuticals, INC. | $29.38 | 2025 | Dawnzera |
| Pfizer INC. | $17.91 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.